Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.…
Septerna (SEPN) Stock Sees Fair Value Lift As Analysts Raise SEP 479 Expectations
Septerna (NASDAQ: SEPN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 134 employees.
The shares were at 38.61 USD on 20 November 2026, up 67.1% over 52 weeks. Its 52-week range is 22.78 USD to 53.34 USD: the price is 27.6% below the high and 69.5% above the low.
Its market capitalisation is 1.84B USD.
Septerna reports return on equity of -12.8%, an operating margin of -76.2% and revenue down 12.2% year over year.
It holds more cash than debt, a net cash position of 456.61M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 59.56 USD is 54.2% above the current price. The next earnings report is expected on 8 March 2027.